Jan Hronek
Sarah Cannon Research Institute, Nashville, TNAuthored Items
November 14, 2017 | November 2017 Vol 8, No 11
The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.
Last modified: June 5, 2018